comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 07:21:54 - browse：591

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Structure Therapeutics oral GLP

leisure time

WSS

Listen: Biogen's potential pivot, & Illumina's next chapter

Covid hospitalizations on the rise, Humana says

Ethical issues complicate the benefits of medical crowdfunding

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Eli Lilly’s Zepbound improved liver scarring in mid

Snackable artificial intelligence, expert AI, and the pharma industry

knowledge

comprehensive

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What American doctors can learn from their Israeli counterparts

Novavax promises a turnaround & Lilly roils the obesity market

Crinetics acromegaly drug succeeds in late

Bright Health sells Medicare Advantage business to Molina

Medicare Advantage's lean provider networks lead CMS complaints

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Hepatitis C has a cure — but many Americans still lack access to it

Covid hospitalizations on the rise, Humana says

entertainment

CMS got Medicare Advantage quality rating wrong, judge rules

FTC loses bid to block Novant's North Carolina hospital merger

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

What drug price negotiations mean for Medicare Part D

The (many) problems with a new study criticizing cancer screening

CMS got Medicare Advantage quality rating wrong, judge rules

leisure time

leisure time

explore

Wikipedia